药物涂层气球用于内血管治疗症状性内静脉疾病:一个多中心随机对照试验
Sheng Guan1, Xu Tong2, Xiaoqing Li2
1Department of Neurointervention, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Radiology
|January 20, 2026
概括
与裸金属支架 (BMS) 相比,药物涂层气球 (DCB) 血管整形显著降低了脑内动脉样硬化疾病患者的复缩率. 这表明DCB是预防中风复发的更安全,更有效的治疗选择.
科学领域:
- 干预神经病学 干预神经病学
- 心血管研究研究心血管研究
- 医疗技术 医疗技术 医学技术
背景情况:
- 复原后裸金属支架 (BMS) 放置是症状性内动脉样硬化疾病 (ICAD) 中中风复发的主要驱动因素.
- 药物涂层气球 (DCB) 血管整形已经成为减少复原率的潜在替代方案.
研究的目的:
- 为了前性地比较DCB血管造形术与BMS安置的疗效和安全性.
- 为了评估症状ICAD和高度狭窄症患者的结果.
主要方法:
- 一项前性随机对照试验,涉及14家中国医院的209名患者.
- 患者被随机分配 (1:1) 接受DCB血管整形或BMS安置.
- 主要结局是6个月的血管图形复缩;次要结局包括症状复缩和复发性缺血事件.
主要成果:
- 在DCB组,6个月的血管图形静止率明显低于11%的比BMS组 (29%) (RR,0.38;P = .006).
- 此外,DCB血管整形也显示了较低的症状复原率 (1%与10%相比;P = .02) 和复发性缺血事件 (4%与13%相比;P = .04).
- 两组之间没有观察到30天中风或死亡率的显著差异 (6%对5%;P = .73).
结论:
- 在患有症状高度ICAD的患者中,DCB血管造形在减少6个月的血管造形和症状复原方面优于BMS安置.
- DCB血管造形显著降低了从手术后30天到1年的复发性缺血事件的风险.
- DCB血管整形为治疗症状性ICAD提供了一个有前途的治疗策略,比BMS提供了更好的结果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
443
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
443
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
503
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
503
Parkinson's Disease: Treatment
1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment
836
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
836
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
510
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
510
Drugs for Treatment of Constipation-Predominant IBS
750
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
750


